Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 2 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 196 Neoplasms 104 Colorectal Neoplasms 91 Stomach Neoplasms 80 Uterine Cervical Neoplasms 71 Carcinoma, Non-Small-Cell Lung 67 Carcinoma, Hepatocellular 54 Prostatic Neoplasms 48 Lung Neoplasms 48 Rectal Neoplasms 46 Esophageal Neoplasms 39 Pancreatic Neoplasms 37 Colonic Neoplasms 36 Ovarian Neoplasms 35 Recurrence 33 Head and Neck Neoplasms 33 Neoplasm Metastasis 28 Motor Activity 28 Multiple Myeloma 27 Small Cell Lung Carcinoma 26 Melanoma 25 Polycystic Ovary Syndrome 24 Lymphoma, Non-Hodgkin 24 Lymphoma 24 Leukemia, Myeloid, Acute 21 Precursor Cell Lymphoblastic Leukemia-Lymphoma 20 Pain 20 Brain Neoplasms 20 Nasopharyngeal Carcinoma 18 Hematologic Neoplasms 17

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Interventional × Small Cell Lung Cancer Recurrent × Clear all

NCT03262454 2022-04-06

Atezolizumab

National Cancer Center, Korea

Phase 2 Unknown

Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡